AbbVie Inc (ABBV)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$226.50

Buy

$228.00

arrow-up$2.29 (+1.02%)

Prices updated at 06 Jun 2026, 00:59 EDT

Prices minimum 15 mins delay

Prices in USD

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new ...

S&P 500

-2.64%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. Robert A. Michael

CEO

Mr. Robert A. Michael

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

57,000

Head office

1 North Waukegan Road

North Chicago

United States

60064-6400

+1 847 932-7900

liz.shea@abbvie.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Frederick H. Waddell Independent Director	0.15m
Ms. Rebecca B. Roberts Independent Director	0.12m
Mr. Thomas C. Freyman Independent Director	0.15m
Mr. Thomas J. Falk Independent Director	0.08m
Mr. Edward J. Rapp Independent Director	0.13m
Ms. Roxanne S. Austin Lead Independent Director	0.18m
Mr. Brett J. Hart Independent Director	0.15m
Dr. Azita Saleki-Gerhardt, B.S.,M.S.,PhD Executive Vice President and Chief Operations Officer	1.05m
Mr. William H.L. Burnside Independent Director	0.13m
Ms. Melody B. Meyer Independent Director	0.16m
Mr. Robert A. Michael Chairman of the Board and Chief Executive Officer	1.70m
Mr. Jeffrey Ryan Stewart Executive Vice President and Chief Commercial Officer	1.32m
Dr. Nicholas J. Donoghoe, M.D. Executive Vice President, Chief Business and Strategy Officer	-
Mr. Scott T. Reents Executive Vice President and Chief Financial Officer	1.12m
Ms. Jennifer L. Davis Independent Director	0.12m
Mr. Perry C. Siatis Executive Vice President, General Counsel and Secretary	-
Dr. Susan E. Quaggin, M.D. Independent Director	0.12m
Dr. Roopal Thakkar, M.D. Executive Vice President, Research and Development and Chief Scientific Officer	1.15m
Mr. David R. Purdue Principal Accounting Officer, Senior Vice President and Controller	-
Mr. Demetris D. Crum Executive Vice President and Chief Human Resources Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	180,779,699
BlackRock Inc	150,698,125
Vanguard Capital Management, LLC	114,880,324
State Street Corp	81,217,516
Vanguard	61,053,903

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2025	-
31 Dec 2025	-
31 Dec 2025	-
30 Sep 2025	-
30 Sep 2025	-
30 Sep 2025	-
12 Aug 2025	-
12 Aug 2025	-
12 Aug 2025	-
05 Aug 2025	-
05 Aug 2025	-
30 Jun 2025	-
30 Jun 2025	-
30 Jun 2025	-
09 May 2025	-
09 May 2025	-
09 May 2025	-
09 May 2025	-
09 May 2025	-
09 May 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.